View More Recent Stories

Mar 11, 2020 04:05PM Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020
Feb 26, 2020 08:00AM Personalis, Inc. to Present at Immuno-Oncology 360˚ Conference
Feb 18, 2020 04:05PM Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
Feb 18, 2020 08:00AM Personalis to Participate at the Cowen 40th Annual Health Care Conference
Feb 11, 2020 01:00PM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Feb 11, 2020 09:13AM Advaxis (ADXS) Gains 8% on Agreement with Personalis for ADXS-503 Trial
Feb 11, 2020 08:00AM Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
Jan 22, 2020 12:15PM Personalis, Inc. to Present at Precision Medicine World Conference 2020
Jan 7, 2020 05:38PM Personalis, Inc. (PSNL) Announces the Launch of the NeXT Dx Test
Jan 7, 2020 05:15PM Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment
Dec 10, 2019 08:00PM Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
Nov 21, 2019 08:00AM Personalis, Inc. to Present at NeoAg Summit US 2019
Nov 19, 2019 04:05PM Personalis to Present at Upcoming Investor Conferences
Nov 19, 2019 08:00AM Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
Nov 17, 2019 04:30PM Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
Nov 13, 2019 04:05PM Personalis Reports Third Quarter 2019 Financial Results
Nov 12, 2019 05:30PM Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services
Nov 6, 2019 01:15PM Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Oct 30, 2019 04:05PM Personalis to Announce Third Quarter 2019 Financial Results on November 13, 2019
Oct 24, 2019 11:00AM Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Oct 8, 2019 11:00AM Personalis, Inc. to Present at Advances in Immuno-Oncology Congress USA 2019
Sep 26, 2019 05:14PM Personalis, Inc. (PSNL) Receives New Order from VA's Million Veteran Program
Sep 26, 2019 04:05PM Personalis Receives New Order from the VA’s Million Veteran Program – Total Awarded to Date Now $145M
Sep 12, 2019 04:08PM Personalis, Inc. (PSNL) Announces Karin Eastham to Board
Sep 12, 2019 04:07PM Personalis Appoints Karin Eastham to Its Board of Directors
Sep 9, 2019 08:00AM Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
Aug 26, 2019 04:32PM Personalis to Participate in the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 13, 2019 04:02PM Personalis Reports Second Quarter 2019 Financial Results
Aug 7, 2019 08:00AM Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study
Aug 1, 2019 04:05PM Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications
Jul 30, 2019 08:00AM Personalis to Announce Second Quarter 2019 Financial Results on August 13, 2019
Jun 24, 2019 04:05PM Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option
Jun 20, 2019 06:14AM Personalis, Inc. (PSNL) Prices 7.92M Share IPO at $17/Sh
Jun 19, 2019 09:10PM Personalis Prices Initial Public Offering of Common Stock
View More Recent Stories